CD8A and neoplasm: Recombinant Listeria monocytogene is mainly widely used in tumor immunotherapy, leveraging its ability to intracellularly replicate within host phagocytes to enhance specific immune responses within the tumor microenvironment, disrupt immune tolerance, and provoke robust and enduring immune reactions from antigen-specific CD8+ T cells [7,8].